Sign In

A subscription to JoVE is required to view this content. Sign in or start your free trial.

In This Article

  • Summary
  • Abstract
  • Introduction
  • Protocol
  • Representative Results
  • Discussion
  • Acknowledgements
  • Materials
  • References
  • Reprints and Permissions

Summary

The processes governing bladder cancer invasion represent opportunities for biomarker and therapeutic development. Here we present a bladder cancer invasion model which incorporates 3-D culture of tumor spheroids, time-lapse imaging and confocal microscopy. This technique is useful for defining the features of the invasive process and for screening therapeutic agents.

Abstract

Bladder cancer is a significant health problem. It is estimated that more than 16,000 people will die this year in the United States from bladder cancer. While 75% of bladder cancers are non-invasive and unlikely to metastasize, about 25% progress to an invasive growth pattern. Up to half of the patients with invasive cancers will develop lethal metastatic relapse. Thus, understanding the mechanism of invasive progression in bladder cancer is crucial to predict patient outcomes and prevent lethal metastases. In this article, we present a three-dimensional cancer invasion model which allows incorporation of tumor cells and stromal components to mimic in vivo conditions occurring in the bladder tumor microenvironment. This model provides the opportunity to observe the invasive process in real time using time-lapse imaging, interrogate the molecular pathways involved using confocal immunofluorescent imaging and screen compounds with the potential to block invasion. While this protocol focuses on bladder cancer, it is likely that similar methods could be used to examine invasion and motility in other tumor types as well.

Introduction

Invasion is a critical step in cancer progression, which is required for metastasis, and is associated with lower survival and poor prognosis in patients. In human bladder cancer, the most common malignancy of the urinary tract which causes about 165,000 deaths per year worldwide, cancer stage, treatment and prognosis are directly related to the presence or absence of invasion1. Around 75% of the cases of bladder cancer are non-muscle invasive and are managed with local resection. In contrast, muscle-invasive bladder cancers (about 25% of all cases) are aggressive tumors with high metastatic rates and are treated with aggressive multimodality t....

Protocol

1. Growing Cancer Spheroids

  1. Growing from cell lines
    1. Culture human bladder cancer cells under conventional adherent cell culture conditions and maintain in a 37 °C incubator supplied with 5% CO2. Maintain cells at <90% confluency.
      NOTE: Culture media used is Dulbecco's modified minimum essential media (DMEM) containing 4.5 g/L D-glucose, L-Glutamine, 110 mg/L sodium pyruvate, and supplied with 10% fetal bovine serum (FBS) throughout this protocol.

Representative Results

Successful creation of invasive bladder cancer tumor spheroid requires the formation of appropriately sized tumor spheroids from cell lines or primary tumors. Figure 2A shows appropriately sized spheroids developed from four human bladder cancer cell lines (UM-UC9, UM-UC13, UM-UC14, 253J, and UM-UC18). Figure 2B shows a tumor spheroid from a BBN-generated mouse bladder tumor embedded in collagen .......

Discussion

Here we describe a 3-D tumor spheroid model that allows real-time observation of bladder cancer invasion which is critical for cancer progression and metastasis. This system is amenable to the incorporation of various stromal and cellular components to allow investigators to better recapitulate the tissue microenvironment where bladder cancer invasion takes place. Bladder cancer spheroids can be generated from various sources such as cell lines (including genetically modified cell lines useful for the examination of sign.......

Acknowledgements

The authors would like to thank the laboratory of Dr. Howard Crawford (University of Michigan) for technical support and providing materials and equipment for this study, and Alan Kelleher for technical support.

This work was funded by grants from the University of Michigan Rogel Cancer Center Core Grant CA046592-26S3, NIH K08 CA201335-01A1 (PLP), BCAN YIA (PLP), NIH R01 CA17483601A1 (DMS).

....

Materials

NameCompanyCatalog NumberComments
Human bladder cancer cell lines UM-UC9, UM-UC13, UM-UC14, UM-UC18, 253J
DMEM cell culture mediumThermo Fisher Scientific11995065
Fetal bovine serum Thermo Fisher Scientific26140079
Antibiotic-Antimycotic (100X)Thermo Fisher Scientific15240062
Trypsin-EDTA (0.25%), phenol redThermo Fisher Scientific25200056
Bovine serum albumin (BSA)Sigma-AldrichA3803
Phosphate-buffered saline (PBS), pH 7.4 Thermo Fisher Scientific10010023
Costar Ultral-low attachment 6-well cluster Corning3471
Conventional inverted microscope Carl Zeiss491206-0001-000General use for cell culture and checking spheroids
Collagen type 1 from rat tail, high concentration Corning354249
Nunc Lab-Tek II Chambered CoverglassThermo Fisher Scientific155382
Confocal microscope Carl ZeissLSM800A confocal miscoscope with climate chamber, multi-location imaging, and Z-stack scanning function 
Cryostat micromtomeLeica BiosystemsCM3050 S
Zen 2 Image processing software Carl Zeiss
Paraformaldehyde solutionElectron Microscopy Sciences15710
ImmEdge Hydrophobic Barrier PAP PenVector Laboratories H4000
O.C.T compound Thermo Fisher Scientific23730571
Hoechst 33342 solution Thermo Fisher Scientific62249
Anti-ATDC (Trim29) antibodySigma-AldrichHPA020053
Anti-Cytokeratin 14 antibodyAbcamab7800
Anti-Vimentin antibodyAbcamab24525
ProLong Diamond Mounting medium

References

  1. American Cancer Society. . The Society. , (2018).
  2. Knowles, M. A., Hurst, C. D. Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nature Reviews Cancer. 15 (1), 25-41 (2015).
  3. <....

Explore More Articles

3D Cell CultureBladder CancerInvasionTherapeuticsTumor SpheroidsCollagenPrimary TumorsCell LinesMicroscopyImmunostaining

This article has been published

Video Coming Soon

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2024 MyJoVE Corporation. All rights reserved